1
Published 2015
Canadian Agency for Drugs and Technologies in Health
... biological mesh, absorbable synthetic mesh, and non-absorbable synthetic mesh. Biological meshes...

2
Published 2015
Canadian Agency for Drugs and Technologies in Health
... biological mesh, absorbable synthetic mesh, and non-absorbable synthetic mesh. Biological meshes...

3
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects: ...Biological Products / therapeutic use...

4
Published 2015
Canadian Agency for Drugs and Technologies in Health
... and safety, as well as evidence-based clinical guidelines, on the practice of switching biologics, both...

6
by Chao, Yi-Sheng, Loshak, Hannah
Published 2019
CADTH
... of biologics and immunomodulators among UC patients naïve to both types of drugs...

7
by Chao, Yi-Sheng, Visintini, Sarah
Published 2018
CADTH
...Up to one-third of inflammatory bowel disease (IBD) patients can experience that biologics become...

8
Published 2017
Canadian Agency for Drugs and Technologies in Health
... and Submission Guidelines for Subsequent Entry Biologics (March, 2014). The CDR team reviewed the information...

10
Published 2017
Canadian Agency for Drugs and Technologies in Health
... and Submission Guidelines for Subsequent Entry Biologics (March, 2014). The CDR team reviewed the information...

11
by Young, Calvin, Campbell, Kaitryn
Published 2019
CADTH
Subjects: ...Biological Products / therapeutic use...

12
by Young, Calvin, Campbell, Kaitryn
Published 2019
CADTH
Subjects: ...Biological Products / therapeutic use...

13
Published 2013
Canadian Agency for Drugs and Technologies in Health
Subjects: ...Biological Assay / methods...

14
Published 2013
Canadian Agency for Drugs and Technologies in Health
Subjects: ...Biological Assay / methods...

15
by Thompson, Wade, Argáez, Charlene
Published 2019
CADTH
...Given the theorized benefits of a top-down approach (early use of biologics), there is growing...

16
by Thompson, Wade, Argáez, Charlene
Published 2019
CADTH
...Given the theorized benefits of a top-down approach (early use of biologics), there is growing...

17
by Young, Calvin, Severn, Melissa
Published 2020
Canadian Agency for Drugs and Technologies in Health
... of the TST for patients with compromised immunity prior to initiating biologic treatment. Additionally...

19
Published 2020
Canadian Agency for Drugs and Technologies in Health
... with immunomodulators or corticosteroids -- but never failed treatment with a biologic -- or have failed or were...

20
by Gray, Casey, McCormack, Suzanne
Published 2019
Canadian Agency for Drugs and Technologies in Health
...Chronic pain serves no biological purpose in contrast with acute pain, which warns of disease...